BioCentury | Dec 19, 2011
Clinical News

Elucigene FH20 regulatory update

...FH. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Dec 19, 2011
Clinical News

LIPOchip regulatory update

...FH. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Sep 26, 2011
Regulation

NICE's diagnostic tests

...an important test for the company. Gen-Probe got the product through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Aug 1, 2011
Clinical News

Elucigene FH20 regulatory update

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Aug 1, 2011
Clinical News

LIPOchip regulatory update

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Jul 25, 2011
Company News

NICE recommends against FH genetic tests

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | May 17, 2010
Company News

Genetic Technologies, Gen-Probe diagnostic news

...products, including its Elucigene range of kits, which Gen-Probe gained through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Dec 7, 2009
Company News

Gen-Probe, Neogen deal

...to focus on human molecular diagnostic opportunities. Gen-Probe gained the business through its acquisition of Tepnel Life Sciences plc...
BioCentury | May 4, 2009
Finance

EPS Watch

...lowered its FY09 GAAP EPS estimate to $1.72-$1.90 from $1.80-$2.05 to reflect its acquisitions of Tepnel Life Sciences plc...
BioCentury | Apr 27, 2009
Finance

Avastin's tender mercies

...so far this year," said portfolio manager Andy Smith. "By the time Genentech, CV Therapeutics, Tepnel...
...8% of the fund, which does not go back in the market on one day." Tepnel Life Sciences plc...
Items per page:
1 - 10 of 71
BioCentury | Dec 19, 2011
Clinical News

Elucigene FH20 regulatory update

...FH. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Dec 19, 2011
Clinical News

LIPOchip regulatory update

...FH. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Sep 26, 2011
Regulation

NICE's diagnostic tests

...an important test for the company. Gen-Probe got the product through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Aug 1, 2011
Clinical News

Elucigene FH20 regulatory update

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Aug 1, 2011
Clinical News

LIPOchip regulatory update

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Jul 25, 2011
Company News

NICE recommends against FH genetic tests

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | May 17, 2010
Company News

Genetic Technologies, Gen-Probe diagnostic news

...products, including its Elucigene range of kits, which Gen-Probe gained through its 2009 acquisition of Tepnel Life Sciences plc...
BioCentury | Dec 7, 2009
Company News

Gen-Probe, Neogen deal

...to focus on human molecular diagnostic opportunities. Gen-Probe gained the business through its acquisition of Tepnel Life Sciences plc...
BioCentury | May 4, 2009
Finance

EPS Watch

...lowered its FY09 GAAP EPS estimate to $1.72-$1.90 from $1.80-$2.05 to reflect its acquisitions of Tepnel Life Sciences plc...
BioCentury | Apr 27, 2009
Finance

Avastin's tender mercies

...so far this year," said portfolio manager Andy Smith. "By the time Genentech, CV Therapeutics, Tepnel...
...8% of the fund, which does not go back in the market on one day." Tepnel Life Sciences plc...
Items per page:
1 - 10 of 71